FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243053025> ?p ?o ?g. }

• W4243053025 abstract "Background: Nephrotic syndrome may be caused by primary (idiopathic) renal disease or by a variety of secondary causes. Patients present with marked edema, proteinuria, hypoalbuminemia, and often hyperlipidemia. Treatment of most patients should include fluid and sodium restriction, oral or intravenous diuretics, and angiotensin-converting enzyme inhibitors. Adults with nephrotic syndrome may benefit from corticosteroid treatment. The treatment of patients with the steroid-resistant nephrotic syndrome (SRNS) and steroid-dependent nephrotic syndrome (SDNS) is challenging. On the basis of suggestions that B lymphocytes are crucial in the pathogenesis of the nephrotic syndrome, rituximab (a monoclonal antibody against CD20 antigen) is used in treatment of these patients. Aim of study: To evaluate the role of rituximaband mycophenolic acid in treatment of patientswith steroid-resistant (SRNS) and steroid-dependent nephrotic syndrome (SDNS), whom not respond or relapse after calcineurin inhibitor (CNI) (tacrolimus or cyclosporine) had been used. Patients and methods: Case series study was done between 2012 - 2015 in AL-Sadder Teaching Hospital Nephrology Center and record 40 patients with different age groups, males and females with different histopathological types (Minimal Change Glomerulonephritis, Focal Segmental Glomerulosclerosis, Mesengeo Prolifrative Glomerulonephritis). These patients were taking prednisilone andor calcineurin inhibitor (tacrolimus “prograf”) or (cyclosporine “sandimmune”), and they get either Steroid Dependent Nephrotic Syndrome or Steroid Resistant Nephrotic Syndrome with frequent admission more than four time per year. To these patients we start rituximab intravenous infusion monthly for at least six months with the use of steroid and mycophenolate mofetil during these six months. The patients followed up for 3-12 months after initiation of rituximab by different investigations and the patients were classified according to their response into complete, partial and no response. After one year stop rituximab treatment, follow the patients clinically and by investigations for (1-2) years to determine which patients get relapse. Results: Majority (80%) of patients with nephrotic syndrome who had good response to rituximab were younger age group < 15 years. Better response to rituximab associated with Minimal Change Glomerulonephritis. There was significant reduction in blood urea, serum creatinine, urine (protein/creatinine) ratio and serum cholesterol. Serum albumin was significant elevated. Response to rituximab was not significantly associated with gender or steroid response. Majority of patients with good response not relapse and need more time for follow up. Relapsing after stopping rituximab not significantly associated with age, gender, histopathological type and steroid response. Conclusion: Rituximab and mycophenolate mofetil used in steroid-resistant nephrotic syndrome to get ride from side effects of calcineurine inhibitor (tacrolimus or cyclosporine). Rituximab and mycophenolate mofetil used in steroid-dependent nephrotic syndrome after calcineurine inhibitorto get ride from side effects of steroid. Improvement in renal function is result from stopping of calcineurine inhibitor (nephrotoxic drugs) and/or from rituximab and mycophenolate mofetil. Cost of rituximab is less than the cost that needed if the patients had frequent admissions to the hospital or developed renal failure and ended with dialysis." @default.
• W4243053025 created "2022-05-12" @default.
• W4243053025 date "2018-01-10" @default.
• W4243053025 modified "2023-10-18" @default.
• W4243053025 title "Rituximab Use in Nephrotic Syndrome" @default.
• W4243053025 cites W2003950996 @default.
• W4243053025 cites W2022859904 @default.
• W4243053025 cites W2045668407 @default.
• W4243053025 cites W2055890849 @default.
• W4243053025 cites W2067799385 @default.
• W4243053025 doi "https://doi.org/10.33140/jcrc/03/01/00001" @default.
• W4243053025 hasPublicationYear "2018" @default.
• W4243053025 type Work @default.
• W4243053025 citedByCount "0" @default.
• W4243053025 crossrefType "journal-article" @default.
• W4243053025 hasBestOaLocation W42430530251 @default.
• W4243053025 hasConcept C126322002 @default.
• W4243053025 hasConcept C128057223 @default.
• W4243053025 hasConcept C203014093 @default.
• W4243053025 hasConcept C2776009029 @default.
• W4243053025 hasConcept C2777747828 @default.
• W4243053025 hasConcept C2778415529 @default.
• W4243053025 hasConcept C2778930706 @default.
• W4243053025 hasConcept C2779338263 @default.
• W4243053025 hasConcept C2779561371 @default.
• W4243053025 hasConcept C2780091579 @default.
• W4243053025 hasConcept C2780368995 @default.
• W4243053025 hasConcept C2780653079 @default.
• W4243053025 hasConcept C2909675724 @default.
• W4243053025 hasConcept C2911091166 @default.
• W4243053025 hasConcept C71924100 @default.
• W4243053025 hasConcept C90924648 @default.
• W4243053025 hasConceptScore W4243053025C126322002 @default.
• W4243053025 hasConceptScore W4243053025C128057223 @default.
• W4243053025 hasConceptScore W4243053025C203014093 @default.
• W4243053025 hasConceptScore W4243053025C2776009029 @default.
• W4243053025 hasConceptScore W4243053025C2777747828 @default.
• W4243053025 hasConceptScore W4243053025C2778415529 @default.
• W4243053025 hasConceptScore W4243053025C2778930706 @default.
• W4243053025 hasConceptScore W4243053025C2779338263 @default.
• W4243053025 hasConceptScore W4243053025C2779561371 @default.
• W4243053025 hasConceptScore W4243053025C2780091579 @default.
• W4243053025 hasConceptScore W4243053025C2780368995 @default.
• W4243053025 hasConceptScore W4243053025C2780653079 @default.
• W4243053025 hasConceptScore W4243053025C2909675724 @default.
• W4243053025 hasConceptScore W4243053025C2911091166 @default.
• W4243053025 hasConceptScore W4243053025C71924100 @default.
• W4243053025 hasConceptScore W4243053025C90924648 @default.
• W4243053025 hasIssue "1" @default.
• W4243053025 hasLocation W42430530251 @default.
• W4243053025 hasOpenAccess W4243053025 @default.
• W4243053025 hasPrimaryLocation W42430530251 @default.
• W4243053025 hasRelatedWork W1964669350 @default.
• W4243053025 hasRelatedWork W2038329662 @default.
• W4243053025 hasRelatedWork W2088670512 @default.
• W4243053025 hasRelatedWork W2258024550 @default.
• W4243053025 hasRelatedWork W2419250504 @default.
• W4243053025 hasRelatedWork W2806711591 @default.
• W4243053025 hasRelatedWork W4236993338 @default.
• W4243053025 hasRelatedWork W4243053025 @default.
• W4243053025 hasRelatedWork W4362685491 @default.
• W4243053025 hasRelatedWork W1984550808 @default.
• W4243053025 hasVolume "3" @default.
• W4243053025 isParatext "false" @default.
• W4243053025 isRetracted "false" @default.
• W4243053025 workType "article" @default.